TB remains the bacterial pathogen responsible for the greatest burden of disease, causing well over a million deaths every year. Control of TB has been set back markedly by the COVID-19 pandemic, and drug resistance is a growing global challenge. Methods of timely diagnosis and shorter treatment regimens remain key goals for clinical TB research, alongside the development of vaccines to prevent TB infection and progression to active disease.
Diagnostics
4 grants
€51.19 M
Vaccines
19 grants
€76.88 M
Drugs
10 grants
€66.76 M
33 grants
€194.83 M
Accelerating TB vaccine development
Preventing latent TB progression
An alternative to BCG for prevention of TB infection
Advancing TB drug development
Statins for TB
A new approach for treatment of TB-related meningitis
Optimising molecular testing for TB
‘Universal’ screening for HIV and TB
Seeking out TB cases
More efficient detection of TB
An alternative to BCG for newborns
